176 related articles for article (PubMed ID: 24618637)
1. Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
Gressette M; Vérillaud B; Jimenez-Pailhès AS; Lelièvre H; Lo KW; Ferrand FR; Gattolliat CH; Jacquet-Bescond A; Kraus-Berthier L; Depil S; Busson P
PLoS One; 2014; 9(3):e91325. PubMed ID: 24618637
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
4. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
5. RPA1 downregulation enhances nasopharyngeal cancer radiosensitivity via blocking RAD51 to the DNA damage site.
Zhang Z; Huo H; Liao K; Wang Z; Gong Z; Li Y; Liu C; Hu G
Exp Cell Res; 2018 Oct; 371(2):330-341. PubMed ID: 30144445
[TBL] [Abstract][Full Text] [Related]
6. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice.
Lacy J; Loomis R; Grill S; Srimatkandada P; Carbone R; Cheng YC
Int J Cancer; 2006 Jul; 119(2):309-16. PubMed ID: 16477627
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
8. RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.
He WL; Li YH; Hou WJ; Ke ZF; Chen XL; Lu LY; Cai SR; Song W; Zhang CH; He YL
World J Gastroenterol; 2014 Aug; 20(29):10094-107. PubMed ID: 25110436
[TBL] [Abstract][Full Text] [Related]
9. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
11. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
13. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
14. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
[TBL] [Abstract][Full Text] [Related]
16. Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Chalret du Rieu Q; Fouliard S; Jacquet-Bescond A; Robert R; Kloos I; Depil S; Chatelut E; Chenel M
Pharm Res; 2013 Oct; 30(10):2640-53. PubMed ID: 23737346
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Adimoolam S; Sirisawad M; Chen J; Thiemann P; Ford JM; Buggy JJ
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19482-7. PubMed ID: 18042714
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF
Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
